PDF(Pubmed)
Abstract：
In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.
摘要：
在亚洲,尤其是越南,房颤是一种常见的心律失常，与中风和全身性栓塞的高风险有关。用于预防房颤患者中风的抗凝治疗可导致出血并发症。为了有效地管理AF，采用适当的抗凝药物和解决可改变的危险因素至关重要.越南临床医生对非维生素K拮抗剂口服抗凝剂（NOAC）特别感兴趣，房颤治疗的最新进展。然而,缺乏比较NOAC的头对头试验使得选择特定NOAC具有挑战性.这篇综述旨在全面概述NOAC在房颤中预防卒中的现有临床证据，以帮助临床医生做出明智的决定并改善房颤患者的治疗结果。本综述的第一部分将介绍越南AF的现状，重点关注房颤患病率并突出临床实践中的差距。此外，本部分广泛讨论了房颤患者卒中一级和二级预防的抗凝策略.
